Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Black Friday Sale
    Black Friday Sale
    HomeNewsBusinessCompaniesAlkem Laboratories launches Ibuprofen, Famotidine tablets in US market

    Alkem Laboratories launches Ibuprofen, Famotidine tablets in US market

    Ibuprofen and Famotidine Tablets is AB-rated generic therapeutic equivalent version of Horizon Medicines LLC's Duexis Tablets, 800 mg/26.6 mg.

    PTI
    August 04, 2021 / 10:47 IST
    Alkem Laboratories | LIC increased stake in the company to 3.42 percent in December quarter from 2.27 percent in September quarter, but HDFC Life Insurance Company's name did not appear in December quarter, which had held 1.07 percent stake in the company in September quarter.
       
       
      26 Aug, 2025 12:21
      Volume
      Todays L/H
      More

      Alkem Laboratories (Alkem) today announced the launch of Ibuprofen and Famotidine Tablets (800 mg/26.6 mg) in the United States, following an approval from the United States Food and Drug Administration (US FDA).

      Ibuprofen and Famotidine Tablets is AB-rated generic therapeutic equivalent version of Horizon Medicines LLC's Duexis Tablets, 800 mg/26.6 mg.

      This is the first generic approval of Duexis Tablets, 800 mg/26.6 mg by the US FDA. The launch is a subject of ongoing litigation.

      PTI
      first published: Aug 4, 2021 10:49 am

      Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

      Subscribe to Tech Newsletters

      • On Saturdays

        Find the best of Al News in one place, specially curated for you every weekend.

      • Daily-Weekdays

        Stay on top of the latest tech trends and biggest startup news.

      Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347